QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
QIAGEN N.V.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 20, 2026
$46.55+0.42 (+0.91%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 24.0
- Dividend yield
- 0.54%
Qiagen statistics
Financials through Dec 31, 2025, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Qiagen | Industry median |
|---|---|---|
| Market Cap | $10.10B | $166.30M |
| Enterprise Value | $10.65B | $88.19M |
| PE Ratio | 23.99 | 20.44 |
| PS Ratio | 4.83 | 3.65 |
| PB Ratio | 2.67 | 2.03 |
| P/TBV Ratio | 14.61 | 2.29 |
| P/FCF Ratio | 22.28 | 17.44 |
| P/OCF Ratio | 15.43 | 12.98 |
Enterprise value
| Measure | Qiagen | Industry median |
|---|---|---|
| EV / Sales | 5.10 | 2.51 |
| EV / EBITDA | 16.15 | 14.65 |
| EV / EBIT | 22.87 | 19.00 |
| EV / FCF | 23.50 | 20.86 |
Income (trailing twelve months)
| Measure | Qiagen | Industry median |
|---|---|---|
| Revenue | $2.09B | $58.34M |
| Gross Profit | $1.30B | $105.94M |
| Operating Income | $465.85M | -$21.40M |
| Pretax Income | $490.27M | -$14.34M |
| Net Income | $424.88M | -$22.46M |
| EBITDA | $659.60M | -$16.91M |
| EPS (Diluted) | $1.94 | -$0.83 |
Margins
| Measure | Qiagen | Industry median |
|---|---|---|
| Gross Margin | 62.2% | 52.9% |
| Operating Margin | 22.3% | -44.0% |
| Pretax Margin | 23.5% | -13.3% |
| Profit Margin | 20.3% | -40.2% |
| EBITDA Margin | 31.6% | -30.2% |
| FCF Margin | 21.7% | -9.27% |
Returns
| Measure | Qiagen | Industry median |
|---|---|---|
| Return on Equity (ROE) | 11.6% | -53.2% |
| Return on Assets (ROA) | 7.10% | -40.9% |
| Return on Invested Capital (ROIC) | 9.92% | -32.4% |
| Return on Capital Employed (ROCE) | 8.07% | -38.1% |
Growth
| Measure | Qiagen | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 5.65% | 5.96% |
| Net Income Growth (YoY) | 408.3% | -35.2% |
| EPS Growth (YoY) | 424.3% | -26.2% |
| FCF Growth (YoY) | -10.5% | 2.34% |
| Revenue Growth (3Y CAGR) | -0.81% | 2.25% |
| Revenue Growth (5Y CAGR) | 2.25% | 6.48% |
| EPS Growth (3Y CAGR) | 1.78% | -0.17% |
| EPS Growth (5Y CAGR) | 4.86% | 3.77% |
Balance sheet
| Measure | Qiagen | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $1.10B | $61.43M |
| Total Debt | $1.65B | $118.52M |
| Net Cash (Debt) | -$555.51M | $15.35M |
| Net Cash Per Share | -$2.56 | $0.66 |
| Equity (Book Value) | $3.78B | $49.09M |
| Book Value Per Share | $17.42 | $1.37 |
| Tangible Book Value | $691.07M | $23.52M |
| Working Capital | $1.48B | $76.81M |
Financial position
| Measure | Qiagen | Industry median |
|---|---|---|
| Current Ratio | 3.90 | 3.34 |
| Quick Ratio | 2.93 | 2.44 |
| Debt / Equity | 0.44 | 0.52 |
| Debt / EBITDA | 2.51 | 3.44 |
| Debt / FCF | 3.65 | 4.89 |
| Net Debt / EBITDA | 0.84 | 2.36 |
| Interest Coverage | 14.01 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Qiagen | Industry median |
|---|---|---|
| Operating Cash Flow | $654.33M | -$12.35M |
| Capital Expenditures | -$201.05M | -$1.08M |
| Free Cash Flow | $453.28M | -$20.22M |
| FCF Per Share | $2.09 | -$0.42 |
Efficiency
| Measure | Qiagen | Industry median |
|---|---|---|
| Asset Turnover | 0.35 | 0.39 |
| Inventory Turnover | 2.72 | 2.70 |
| Revenue Per Employee | $366.67K | $404.87K |
| Profits Per Employee | $74.54K | -$703.34K |
| Employee Count | 5,700 | 74 |
Dividends and yields
| Measure | Qiagen | Industry median |
|---|---|---|
| Earnings Yield | 4.21% | -23.3% |
| FCF Yield | 4.49% | -8.72% |
| Dividend Yield | 0.54% | 1.82% |
| Buyback Yield | 2.77% | -0.59% |
| Shareholder Yield | 3.31% | 0.00% |
| Dividend Per Share | $0.25 | $0.83 |
| Years of Dividend Growth | 0 | 0 |
| Payout Ratio | 12.8% | 46.5% |
| FCF Payout Ratio | 12.0% | 47.6% |
Shares
| Measure | Qiagen | Industry median |
|---|---|---|
| Shares Outstanding | 216,921,000 | 58,127,000 |
| Shares Change (YoY) | -2.60% | 10.9% |
| Float | 216,921,000 | 49,136,700 |
| Shares Held by Insiders | 0.00% | 11.6% |
Taxes
| Measure | Qiagen | Industry median |
|---|---|---|
| Income Tax | $65.39M | $79.87K |
| Effective Tax Rate | 13.3% | 20.6% |
Scores
| Measure | Qiagen | Industry median |
|---|---|---|
| Graham Number | $27.57 | $18.73 |
| Graham Upside | -40.8% | -45.1% |
| Altman Z-Score | 3.89 | -0.22 |
| Piotroski F-Score | 8 | 4 |
| Beneish M-Score | -2.60 | -2.62 |
Calculated by StockData from Qiagen's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.